Macroscopic serosal invasion and small tumor size as independent prognostic factors in stage IIA colon cancer

10573 Background: We conducted a retrospective study pooling data from two clinical trials in high risk STS patients with the objective to compare two different age groups: 15 - 29 years (AYA population) and ≥ 30 years. The aim was to determine prognostic factors for the AYA population. Methods: Patients selected for analysis were treated in two randomized trials of adjuvant chemotherapy in STS (EORTC 62771 and 62931). A total of 793 patients were included with a median follow-up (FU) of 8.74 years (AYA population: n = 161, median FU 9.46 years; patients ≥ 30 years: n = 632, median FU 8.62 years). Study endpoints were overall survival (OS) and relapse-free survival (RFS). The variables of the multivariate analysis were gender, subtype and grade, tumor size and localization (limb vs. other), absence or presence of local recurrence and treatment (control arm vs. adjuvant chemotherapy). Results: Patients’ characteristics were globally similar with two exceptions, histological subtype (p = 0.0043) and tumor size (p < .0001). The commonest sarcoma subtype in the AYA population was synovial sarcoma (29 %), whereas leiomyosarcoma (18 %), malignant fibrous histiocytoma (MFH, 16 %) and liposarcoma (15 %) were more frequent in patients ≥ 30 years. For OS, independent favorable prognostic factors were low grade and small tumor size for both groups; radical resection and MFH or liposarcoma subtype were factors of favorable prognosis for patients ≥ 30 years only. For RFS, favorable prognostic factors were small tumor size and low grade for both groups; tumor location in the extremities was a factor of favorable prognosis for the AYA population only, whereas radical resection and adjuvant chemotherapy treatment were favorable factors for patients ≥ 30 years only. Conclusions: On the basis of these data, significant differences could be found concerning prognostic factors between the AYA population and older patients. Interestingly, adjuvant chemotherapy was associated with improved RFS only in patients ≥ 30 years. The results may have further implications on the treatment of STS patients in different age groups as well as the design of future clinical trials. No significant financial relationships to disclose.

Download Full-text

Impact of surgical margins on survival in cutaneous sarcomas: A nationwide study of French Sarcoma Group (FSG) from NETSARC Database.

Journal of Clinical Oncology ◽

10.1200/jco.2021.39.15_suppl.e23537 ◽

2021 ◽

Vol 39 (15_suppl) ◽

pp. e23537-e23537

Author(s):

Mélanie Saint-Jean ◽

Audrey Michot ◽

Andrea Cavalcanti ◽

Gauthier Decanter ◽

Thomas Meresse ◽

...

Keyword(s):

Prognostic Factors ◽

Median Time ◽

Tumor Size ◽

Multivariate Analyses ◽

Local Relapse ◽

Young Age ◽

Margin Status ◽

Undifferentiated Sarcoma ◽

Small Tumor ◽

Small Tumor Size

e23537 Background: R0 surgery in reference centers is the cornerstone for sarcomas treatment with better local control and survival and is mandatory for ESMO-EURACAN and NCCN guidelines. The medical community is out on this issue for cutaneous sarcomas, if they have to follow suit. This retrospective descriptive study focused on margin status and local relapse-free survival (LRFS) and overall survival (OS) of patients (pts) with cutaneous sarcomas. Methods: Between 01/01/10 and 30/12/17, surgery was performed on 2044 pts with cutaneous sarcomas from 20 centers. Data were collected from the NETSARC national network database ( http://netsarc.sarcomabcb.org ). Diagnosis of cutaneous sarcoma was reviewed and histologically confirmed by a local expert pathologist of RRePS (“Network for expert pathology diagnosis in sarcoma”). Dermatofibrosarcoma, Kaposi sarcoma and rare subtypes (< 20 cases in the database) were excluded. Univariate analyses were conducted using log rank test or Cox test. Multivariate analyses were conducted using Cox test. Age and tumor size were analyzed as continuous values. Two-sided significant p level was set at < 0.05. Results: Mean age was 66 years. Primary tumor was localized in lower limb, trunk wall, head and neck and upper limb for 30%, 26%, 26% and 18% pts respectively. Main subtypes were leiomyosarcoma, undifferentiated sarcoma, and myxofibrosarcoma for 29%, 29%, and 14% pts respectively. Angiosarcoma was the subtype of 9% of the patients (n = 193). Mean size was 45 mm. FNCLCC grade was 1, 2, and 3 for 14%, 29.5%, and 24% tumors respectively. Before surgery, imaging and biopsy were performed for 21% and 51% pts respectively. Surgery was carried out in a NETSARC center for 26% of the pts. Margin status after initial surgery was R0, R1, and R2 for 35% (n = 724), 34% (n = 696), and 12% pts (n = 246) respectively. Re-excision was performed for 34% (703/2044 pts), leading to a subsequent R0 margin for 74% of them (523/703 pts, equivalent to 26% of the overall population). Local relapse occurred for 21% of pts after a median time of 10 months. Metastatic relapse occurred for 13% of pts after a median time of 11 months. One hundred and ninety-three pts (9%) died. Median follow-up was 12 months. In multivariate analyses, statistically significant favorable prognostic factors for LRFS were: young age, small tumor size and non-angiosarcoma subtype. Significant prognostic factors associated with longer OS were: young age, small tumor size, non-angiosarcoma subtype, FNCLCC grade (1 vs 2 and 1 vs 3) and initial R0 surgery. Conclusions: Cutaneous sarcomas share same favorable clinical prognostic factors than non-cutaneous sarcomas. Quality of surgery remains the mainstay for OS.

Download Full-text

Impact of Primary Tumor Size on Prognosis in Patients With Metastatic Renal Cell Carcinoma Receiving Cytoreductive Nephrectomy: A Population Study of a Chinese Center and the US SEER Database

Technology in Cancer Research & Treatment ◽

10.1177/15330338211019507 ◽

2021 ◽

Vol 20 ◽

pp. 153303382110195

Author(s):

Weixing Jiang ◽

Jianzhong Shou ◽

Hongzhe Shi ◽

Li Wen ◽

Huijuan Zhang ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Prognostic Factors ◽

Tumor Size ◽

Primary Tumor ◽

Protective Factor ◽

Seer Database ◽

Cytoreductive Nephrectomy ◽

Small Tumor ◽

Chinese Cohort ◽

Small Tumor Size

Background: The relationship between the size of the primary tumor and the prognosis of patients with metastatic renal cell carcinoma (mRCC) is unclear. In this study, we aimed to investigate the significance of the size of the primary tumor in mRCC. Methods: We retrospectively reviewed the data of patients with mRCC who underwent cytoreductive nephrectomy (CN) from 2006 to 2013 in a Chinese center (n = 96) and those in the Surveillance, Epidemiology, and End Results (SEER) database (from 2004 to 2015, n = 4403). Tumors less than 4 cm in size were defined as small. Prognostic factors were analyzed using univariate and multivariate Cox proportional hazards regression analyses. Results: Patients with small tumors had a longer overall survival than other patients, both in the Chinese cohort (median, 30.0 vs 24.0 months, P = 0.026) and the SEER cohort (median, 43.0 vs 23.0 months, P < 0.001). After adjusting for other significant prognostic factors, small tumor size was still an independent protective factor in the Chinese cohort (adjusted hazard ratio [HR], 0.793; 95% confidence interval [CI]: 0.587–0.998, P = 0.043). In the SEER cohort, multivariate analysis showed that small tumor size was also an independent protective factor (HR, 0.880; 95% CI: 0.654–0.987, P = 0.008). In addition, as a continuous variable, a 1 cm elevation in tumor size translated into a 3.8% higher risk of death (HR, 1.038; 95% CI, 1.029–1.046; P < 0.001). Conclusion: Patients with small tumors may have a favorable prognosis after CN for mRCC. Although CN is not a standard protocol in mRCC, small tumor size may be a candidate when we are deciding to perform CN because of the potential benefit for OS.

Download Full-text

Outcome of multidisciplinary treatment of peripheral primitive neuroectodermal tumor

Scientific Reports ◽

10.1038/s41598-020-72680-6 ◽

2020 ◽

Vol 10 (1) ◽

Author(s):

Yidi Liu ◽

Yan Yuan ◽

Fuquan Zhang ◽

Ke Hu ◽

Jie Qiu ◽

...

Keyword(s):

Overall Survival ◽

Tumor Size ◽

Therapeutic Approach ◽

Univariate Analysis ◽

Multidisciplinary Treatment ◽

College Hospital ◽

Small Tumor ◽

Medical College ◽

Treatment Plans ◽

Small Tumor Size

Abstract Peripheral primitive neuroectodermal tumors (PNETs) constitute very rare and aggressive malignancies. To date, there are no standard guidelines for management of peripheral PNETs due to the paucity of cases arising in various body sites. Therapeutic approach is derived from Ewing sarcoma family, which currently remains multimodal. Our study retrospectively analyzed 86 PNET patients from February 1, 1998 to February 1, 2018 at Peking Union Medical College Hospital with an additional 75 patients from review of literature. The clinicopathologic and treatment plans associated with survival was investigated. Surgery, chemotherapy, female sex, small tumor size, no lymph node metastasis, R0 surgical resection, (vincristine + doxorubicin + cyclophosphamide)/(isophosphamide + etoposide) regimen, and more than 10 cycles of chemotherapy were associated with improved overall survival in univariate analysis. Surgery, more than 10 cycles of chemotherapy, and small tumor size were independent prognostic factors for higher overall survival. Our data indicates that multimodal therapy is the mainstay therapeutic approach for peripheral PNET.

Download Full-text

P31 Prognostic significance of vascular tumor emboli in 1518 breast carcinoma patients with small tumor size (≤3 cm)

European Journal of Cancer ◽

10.1016/s0959-8049(97)89249-0 ◽

1998 ◽

Vol 34 ◽

pp. S21

Author(s):

J.-Y. Pierga ◽

A. Vincent-Salomon ◽

M. Cousineau ◽

B. Zafrani ◽

B. Asselain ◽

...

Keyword(s):

Breast Carcinoma ◽

Tumor Size ◽

Prognostic Significance ◽

Vascular Tumor ◽

Small Tumor ◽

Tumor Emboli ◽

Small Tumor Size

Download Full-text

Improvement of the primary efficacy of microwave ablation of malignant liver tumors by using a robotic navigation system

Radiology and Oncology ◽

10.2478/raon-2020-0033 ◽

2020 ◽

Vol 54 (3) ◽

pp. 295-300

Author(s):

Jan Schaible ◽

Benedikt Pregler ◽

Niklas Verloh ◽

Ingo Einspieler ◽

Wolf Bäumler ◽

...

Keyword(s):

Tumor Size ◽

Microwave Ablation ◽

Liver Tumors ◽

Multiple Logistic Regression Analysis ◽

Percutaneous Ablation ◽

Primary Efficacy ◽

Robotic Navigation ◽

Liver Malignancies ◽

Small Tumor ◽

Small Tumor Size

AbstractBackgroundThe aim of the study was to assess the primary efficacy of robot-assisted microwave ablation and compare it to manually guided microwave ablation for percutaneous ablation of liver malignancies.Patients and methodsWe performed a retrospective single center evaluation of microwave ablations of 368 liver tumors in 192 patients (36 female, 156 male, mean age 63 years). One hundred and nineteen ablations were performed between 08/2011 and 03/2014 with manual guidance, whereas 249 ablations were performed between 04/2014 and 11/2018 using robotic guidance. A 6-week follow-up (ultrasound, computed tomography and magnetic resonance imaging) was performed on all patients.ResultsThe primary technique efficacy outcome of the group treated by robotic guidance was significantly higher than that of the manually guided group (88% vs. 76%; p = 0.013). Multiple logistic regression analysis indicated that a small tumor size (≤ 3 cm) and robotic guidance were significant favorable prognostic factors for complete ablation.ConclusionsIn addition to a small tumor size, robotic navigation was a major positive prognostic factor for primary technique efficacy.

Download Full-text

Small tumor size and limited smoking history predicts activated EGFR-Stat3 in early stage non-small cell lung cancer

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.7075 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 7075-7075

Author(s):

E. B. Haura ◽

Z. Zheng ◽

A. Cantor ◽

G. Bepler

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Tumor Size ◽

Early Stage ◽

Small Cell ◽

Smoking History ◽

Small Cell Lung ◽

Small Tumor ◽

Small Tumor Size

Download Full-text

Effect of very small tumor size on cancer-specific mortality in node-positive melanoma.

Journal of Clinical Oncology ◽

10.1200/jco.2017.35.15_suppl.e21059 ◽

2017 ◽

Vol 35 (15_suppl) ◽

pp. e21059-e21059

Author(s):

Xinyang Liu ◽

Zhichao Wang ◽

Qingfeng Li

Keyword(s):

Tumor Size ◽

Reference Group ◽

Multivariable Analysis ◽

Hazard Ratio ◽

Primary Study ◽

Ratio Test ◽

Small Tumor ◽

Specific Mortality ◽

Cancer Specific Mortality ◽

Small Tumor Size

e21059 Background: Traditionally, larger tumor size and lymph node (LN) involvement have been considered independent predictors of mortality in melanoma. We aimed to characterize the interaction between tumor size and LN involvement in melanoma specific mortality. In particular, we evaluated whether very small tumor size represented a particularly aggressive disease variant compared with larger LN-positive melanoma. Methods: Using Surveillance, Epidemiology and End Results registry data, we identified 57,223 patients (aged 18-85 years) diagnosed between 1998 and 2012 with histologically confirmed nonmetastatic melanoma treated with surgery. Primary study variables were tumor size, LN involvement, and their corresponding interaction term. Kaplan-Meier methods, adjusted Cox proportional hazards models with interaction terms were performed. Potential confounders included age, sex, year of diagnosis, marital status and number of LN dissected. Results: Median follow-up was 48 months. In multivariable analysis, there was significant interaction between tumor size and LN involvement ( P < 0.0001) using the likelihood ratio test and Wald test. In the absence of LN involvement (n = 54,922), the hazard ratio (HR) increased monotonically with increasing tumor size. Among patients with LN involvement (n = 2,301), using the smallest tumors as the reference group, hazard ratio of cancer specific mortality decreased unexpectedly in 0.01-1.00mm tumors (HR 0.61, p = 0.022) and 1.01-2.00mm tumors (HR 0.58, p = 0.007), and reached to a similar level in tumors sized 2.01-4.00mm (HR 0.81, p = 0.280), and subsequently increased in tumors sized larger than 4.00mm (HR 1.57, p = 0.016). Conclusions: In LN positive melanoma, very small tumors may predict for higher mortality compared with larger tumors. These results should be validated in future database studies. Table. Effect of tumor size in LN positive and LN negative melanoma. [Table: see text]

Download Full-text